Core Viewpoint - The stock of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. experienced a decline of 2.10% on January 19, with a trading volume of 160 million yuan, indicating a potential concern regarding investor sentiment and market performance [1]. Financing Summary - On January 19, Boyuan received a financing buy-in amounting to 16.84 million yuan, while the financing repayment was 18.71 million yuan, resulting in a net financing outflow of 1.86 million yuan [1]. - As of January 19, the total financing and securities lending balance for Boyuan was 155 million yuan, with the financing balance accounting for 3.41% of the circulating market value, which is above the 70th percentile of the past year, indicating a relatively high level [1]. - In terms of securities lending, there were no shares repaid or sold on January 19, with the securities lending balance also at zero, placing it in the 90th percentile of the past year, suggesting a high level of inactivity in this area [1]. Company Overview - Boyuan, established on August 6, 2008, is located in Shouguang City, Shandong Province, and specializes in the research, production, and sales of fine chemicals, including organic and inorganic iodides, precious metal catalysts, and luminescent materials [2]. - The company's revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2]. - For the period from January to September 2025, Boyuan reported a revenue of 1.073 billion yuan, reflecting a year-on-year growth of 6.60%, while the net profit attributable to shareholders decreased by 22.53% to 132 million yuan [2]. Shareholder Information - As of January 9, 2025, Boyuan had 8,920 shareholders, a decrease of 5.03% from the previous period, with an average of 5,946 circulating shares per person, which is an increase of 5.29% [2]. - The company has distributed a total of 88.41 million yuan in dividends since its A-share listing [3]. - Notable new institutional shareholders include China Aviation New Start Flexible Allocation Mixed A, holding 1.3456 million shares, and Hong Kong Central Clearing Limited, holding 964,400 shares, among others [3].
博苑股份1月19日获融资买入1684.66万元，融资余额1.55亿元